ASPREE is a randomized, double-blind, placebo-controlled clinical trial investigating the effects of 100mg of daily low-dose aspirin in 19,114 healthy older adults, aged ≥70 years (≥65 years for US participants) at enrollment.

ASPREE-XT is an ongoing observational follow-up study to examine the long-term effects of aspirin on various health outcomes, including cancer, dementia, and physical disability. The study also seeks to identify other lifestyle, genetic, environmental, and health-related factors contributing to healthy aging.

Additional details about the adjudication can be found in the ASPREE publication: Ryan, Joanne et al. “Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.” Neurology vol. 95,3 (2020): e320-e331. doi:10.1212/WNL.000000000000927.  PubMed Link